CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Fluticasone Propionatedrug
Likely dose
Fluticasone Propionate 186 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03591068
NCT03591068Phase 3Completed
CompareCT.gov

A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video

Optinose US Inc.·interventional·Posted Jul 18, 2018·Updated Aug 3, 2020

In Brief

A Phase 3 clinical trial evaluating Fluticasone Propionate for Nasal Polyposis. Completed, enrolled 11 participants across 2 sites.

Detailed Summary

This is a 24-week, open-label, multi-center study designed to assess the efficacy and safety of OPN-375 186 μg twice a day in subjects with nasal polyps using Nasoendoscopic video. The total planned number of subjects is approximately 10, with each subject receiving OPN-375 186 μg twice a day.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasal Polyposis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJul 18, 2018
Enrollment StartJun 7, 2018
Primary CompletionFeb 22, 2019
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 8.0 years ago

Interventions

Fluticasone Propionatedrug

OPN-375 186 μg BID, Delivered via exhalation delivery system